Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170321 | 0.82 | MMP1 (0.39) | HSD11B1L3MBTL1LMNAALDH1A1 | |
| SCHEMBL18716489 | 0.81 | HSD11B1 (0.39) | HSD11B1L3MBTL1LMNAALDH1A1KCNH2 | |
| SCHEMBL18686866 | 0.81 | HSD11B1 (0.39) | HSD11B1L3MBTL1LMNAALDH1A1KCNH2 | |
| SCHEMBL18716488 | 0.81 | HSD11B1 (0.39) | HSD11B1L3MBTL1LMNAALDH1A1KCNH2 | |
| SCHEMBL9372634 | 0.80 | HSD11B1 (0.38) | HSD11B1L3MBTL1LMNAALDH1A1KCNH2 | |
| SCHEMBL9368218 | 0.80 | HSD11B1 (0.38) | HSD11B1L3MBTL1LMNAALDH1A1KCNH2 | |
| SCHEMBL9368025 | 0.80 | HSD11B1 (0.38) | HSD11B1L3MBTL1LMNAALDH1A1KCNH2 | |
| SCHEMBL8870143 | 0.79 | HSD11B1 (0.40) | HSD11B1L3MBTL1ALDH1A1KCNH2TSHR | |
| SCHEMBL8620053 | 0.79 | HSD11B1 (0.40) | HSD11B1L3MBTL1ALDH1A1KCNH2TSHR | |
| SCHEMBL8620049 | 0.79 | HSD11B1 (0.40) | HSD11B1L3MBTL1ALDH1A1KCNH2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1942109-A1 | TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | ABCC1, AZI2, TPD52L2 | HSD11B1 1690/4885L3MBTL1 1661/4885LMNA 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.